HHV8
Reactivity: Human Herpesvirus 8 (HHV-8)
Host: Rat
Monoclonal
LN53
CF®647
Application Notes
Immunohistochemistry: Use at 1/25-1/50 dilution in an ABC method (30 to 60 minutes atroom temperature). Formalin fixed paraffin embedded tissue sections require high temperature antigenunmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining. Recommended Positive Control: Kaposi's sarcoma. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Format
Liquid
Buffer
Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Storage Comment
Store the antibody undiluted at 2-8 °C.
Target
HHV8
(Herpes Virus Type 8 (HHV8))
Alternative Name
Herpes Virus Type 8 / HHV8
Target Type
Virus
Background
HHV8 has been found to be associated with three different diseases observed in AIDS patients, kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma.Synonyms: HHV-8, KHSV